Agoracom: Small Cap Investment - Zenith Epigenetics - Re: Zenith Presentation at AACR Meeting April 10-15

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Back To Forum List View

Zenith Presentation at AACR Meeting April 10-15

BearDownAZ

Apr 09, 2021 02:43PM

Toinv

Rank: President [?]

Points: 4445 [?]

Votes: 35 Score: 3.7 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith Presentation at AACR Meeting April 10-15

in response to

Zenith Presentation at AACR Meeting April 10-15

BearDownAZ

posted on Apr 11, 2021 11:30AM

Given the conclusion of the abstract -

We conclude that ZEN-3694 in combination with PARP inhibitors is a novel therapeutic strategy in ER+ breast cancer patients progressing on CDK4/6 inhibitors and a promising approach in HR proficient breast cancer.

How far do we think zen3694 is from being an approved therapy for those conditions?

Toinv

3 Recommendations

Re: Zenith Presentation at AACR Meeting April 10-15

fuzzyjr

Apr 11, 2021 02:24PM

Re: Zenith Presentation at AACR Meeting April 10-15

KayakerBC

Apr 12, 2021 09:09AM

Re: Zenith Presentation at AACR Meeting April 10-15

fuzzyjr

Apr 12, 2021 10:03AM